Invex Therapeutics Limited logo

Invex Therapeutics Limited (IXC)

Market Closed
ASX ASX
- Market Cap
- P/E Ratio
- Div Yield
20,000 Volume
- Eps
Want to track IXC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

IXC is not paying dividends to its shareholders.
The last earnings report, released on Feb 05, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

Invex Therapeutics Limited (IXC) FAQ

On which exchange is it traded?

Invex Therapeutics Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is IXC.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Invex Therapeutics Limited ever had a stock split?

No, there has never been a stock split.

Invex Therapeutics Limited Profile

Software Industry
Information Technology Sector
Alfred Chong CEO
ASX Exchange
Q496BJ108 CUSIP
AU Country
9 Employees
8 Dec 2023 Last Dividend
- Last Split
- IPO Date

Overview

Nanoveu Limited is an innovative technology enterprise specializing in the development and commercialization of advanced nanotechnology applications tailored for consumer devices. Founded in 2012 and headquartered in Perth, Australia, the company has established its presence across the Americas and Asia. Nanoveu Limited focuses on leveraging cutting-edge nanotechnology to create products that offer significant benefits in terms of health, safety, and user experience. The company’s mission is to integrate nanotechnology into everyday consumer devices, enhancing their functionality and adding value to users' lives across the globe.

Products and Services

  • Nanoshield:
  • An antiviral protector developed by Nanoveu, Nanoshield represents the company’s commitment to health and safety in the digital age. It's specifically designed to fit various mobile phone screen covers and cases, offering a layer of protection against harmful viruses. Furthermore, Nanoshield is available as a commercial film that can be applied to a wide range of surfaces, extending its protective benefits beyond just personal devices to encompass environments such as workplaces and public areas.

  • EyeFly3D:
  • EyeFly3D is a novel product that transforms 2D digital displays into 3D, enabling a glasses-free 3D viewing experience. Compatible with Apple iPhones and Google Pixel 3 phones, this product leverages proprietary technology to provide users with a rich, immersive visual experience without the need for traditional 3D glasses. EyeFly3D exemplifies Nanoveu's dedication to enhancing digital media consumption through innovative uses of nanotechnology.

  • EyeFyx:
  • Applying its nanotech expertise to the field of vision correction, Nanoveu has developed EyeFyx, a visionary product designed to improve the clarity of digital displays for viewers with specific eyesight limitations. EyeFyx represents a convergence between technology and healthcare, offering a non-invasive solution for enhancing visual comprehension without the need for prescription glasses or contact lenses. This product underscores the company’s innovative approach to addressing everyday challenges through advanced technology.

Contact Information

Address: 1/18 Olive Street
Phone: 61 8 6244 9095